Key result
Initial NOAC use for isolated distal DVT matches proximal DVT at ~56%.
Why the study?
Isolated distal deep vein thrombosis is presumed to be more benign than proximal DVT or pulmonary embolism, suggesting a need for different management approaches.
Does the clinical profile and real-world anticoagulant management of isolated distal DVT differ from proximal DVT or pulmonary embolism?
Observational (n=5,772)
Yes
Does the clinical profile and real-world anticoagulant management of isolated distal DVT differ from proximal DVT or pulmonary embolism?
In real-world practice, patients with isolated distal DVT receive anticoagulant therapy at similar rates to those with proximal DVT or PE, despite having a more benign clinical profile and fewer risk factors.
Answers are grounded in this paper and cite their sources.
Similar NOAC use for isolated distal DVT despite benign profile warrants caution; leaves open optimal strategies pending randomized trials.
Isolated distal deep vein thrombosis (IDDVT) is presumed to be more benign than proximal DVT (PDVT) or pulmonary embolism (PE), suggesting a need for different management approaches. This subgroup analysis of the RE-COVERY DVT/PE global, observational study investigated patient characteristics, hospitalization details, and anticoagulant therapy in patients with IDDVT in real-world settings in 34 countries enrolled from January 2016 to May 2017. Data were analyzed descriptively according to the type and location of the index venous thromboembolism (VTE): IDDVT, PDVT ± distal DVT (DDVT), and PE ± DVT. Of the 6,095 eligible patients, 323 with DVT located outside the lower limb and no PE were excluded. Of the remaining 5,772 patients, 17.6% had IDDVT, 39.9% had PDVT ± DDVT, and 42.5% had PE ± DVT. IDDVT patients were younger and had fewer risk factors for VTE than the other groups. Other comorbidities were less frequent in the IDDVT group, except for varicose veins, superficial thrombophlebitis, and venous insufficiency. IDDVT patients were less likely to be diagnosed in an emergency department (22.3 vs. 29.7% for PDVT ± DDVT and 45.4% for PE ± DVT) or hospitalized for VTE (29.2 vs. 48.5% for PDVT ± DDVT and 75.0% for PE ± DVT). At hospital discharge or 14 days after diagnosis (whichever was later), non-vitamin K antagonist oral anticoagulants were the most commonly used anticoagulants (55.6% for IDDVT, 54.7% for PDVT ± DDVT, and 52.8% for PE ± DVT). Although differences in patient characteristics, risk factors, and clinical management were identified, anticoagulant treatment of IDDVT was almost equal to that of PDVT or PE. Prospective studies should investigate whether, in a global perspective, this is an appropriate use of anticoagulants.
No takes yet. Share an insight, caveat, or question.
Schellong et al. (2021) conducted an observational in Acute venous thromboembolism (isolated distal DVT, proximal DVT, or pulmonary embolism) (n=5,772). Anticoagulant therapy vs. Proximal DVT or Pulmonary Embolism was evaluated on Use of non-vitamin K antagonist oral anticoagulants at hospital discharge or 14 days after diagnosis. Initial anticoagulant therapy for isolated distal deep vein thrombosis was almost equal to that for proximal deep vein thrombosis, with 55.6% and 54.7% of patients receiving NOACs, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: